Delivery Order SPE2DB25D3012-SPE2DB25FWWYV
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $14,061.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), carries an ultimate completion date of September 3, 2025, and involves no set-aside designation....
- The Defense Logistics Agency awarded a $46.9K delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The order will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of October 6, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for Tezspire 210 mg/1.91 mL pen injectors valued at $2,343.59 with a firm fixed price contract type. The order is scheduled for completion by September 29, 2025, with performance at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This is a non-set-aside competitive award issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors on August 27, 2025. This competitively awarded, firm fixed-price contract is a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to the company's location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of September 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The pharmaceutical products will be delivered to AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,687.18 for Tezspire 210 mg/1.91 mL pen injectors, with a completion date of August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment of severe asthma, representing the type of high-value...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors on August 8, 2025, with a completion date of August 29, 2025. This firm fixed-price, non-set-aside contract was issued under a competitive procurement process and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Tezspire is a biologic medication used in the treatment of moderate-to-severe asthma, representing the type of...
- The Defense Logistics Agency awarded a $4,687.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of August 27, 2025. This non-set-aside contract represents a single delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The product will be delivered to...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,374.36 by the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This firm fixed-price, competitively awarded contract (without set-aside designation) is scheduled for completion by August 13, 2025, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FWWYVDelivery Order
The Defense Logistics Agency (DLA) awarded a $9,374.36 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors on April 22, 2025, with completion scheduled for May 13, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999, which extends through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. Tezspire is a biologic medication used to treat moderate-to-severe asthma, representing the type of specialty pharmaceutical products that AmerisourceBergen supplies through its federal contracts supporting the Defense Health Agency and other military healthcare systems. As a major pharmaceutical distributor and established federal contractor, AmerisourceBergen has demonstrated capability to fulfill federal medical procurement requirements through competitive awards across a diverse portfolio of medications and medical supplies, ranging from brand-name drugs to vaccines and specialized medical devices supporting global military operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.4k | 4/22/25 |